Company Filing History:
1 out of 932 
1 out of 322 
1 out of 622 
Years Active: 2002-2010
Title: Andrew Grupe: Innovator in Genomic Research
Introduction
Andrew Grupe is a notable inventor based in Redwood City, CA. He has made significant contributions to the field of genomic research, holding a total of 3 patents. His work focuses on understanding the genetic basis of phenotypic traits and disease susceptibility.
Latest Patents
One of Andrew's latest patents is titled "System and method for predicting chromosomal regions that control phenotypic traits." This innovative method involves associating phenotypes with candidate chromosomal regions in an organism's genome. The process includes deriving a phenotypic data structure that represents differences in phenotypes among various strains. Additionally, a genotypic data structure is established, which corresponds to selected loci in the genome. By comparing these data structures, Andrew's method identifies candidate chromosomal regions that correlate with specific phenotypic traits.
Another significant patent is related to "TCF-1 nucleotide sequence variation." This patent outlines methods and reagents for determining sequence variants at the TCF-1 locus. This work is crucial for identifying individuals at risk for Th1 diseases, such as type 1 diabetes and multiple sclerosis, as well as Th2 diseases like allergic asthma and atopy.
Career Highlights
Andrew has worked with prominent companies in the biotechnology sector, including Syntex Inc. and Roche Palo Alto LLC. His experience in these organizations has allowed him to develop and refine his innovative ideas in genomic research.
Collaborations
Throughout his career, Andrew has collaborated with esteemed colleagues, including Gary A. Peltz and Leyi Gong. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Andrew Grupe is a distinguished inventor whose work in genomic research has the potential to impact the understanding of genetic traits and disease susceptibility. His innovative patents reflect his commitment to advancing the field and improving health outcomes.